Meloni M, Giurato L, Monge L, Miranda C, Scatena A, Ragghianti B, Silverii GA, Vermigli C, De Cassai A, Volpe A, Tramonta R, Medea G, Bordieri C, Falcone M, Stefanon L, Bernetti A, Cappella C, Gargiulo M, Lorenzoni W, Scevola G, Stabile E, Da Ros R, Murdolo G, Bianchini E, Gaggia F, Gauna C, Romeo F, Apicella M, Mantuano M, Monami M, Uccioli L
Lancet 140-6736(23): 01200-X
Contra-indications and contra-actions
In a single piece, he concisely captures: the state of the field the most important clinical trials where the pipeline is headed These Clinical trials are raising the bar and expanding future treatment options: Retatrutide ~24% weight loss (triple agonist) MariTide 1216% weight loss (GLP-1 + GIP antagonist) CagriSema up to 20% weight loss + ~2% HbA1c drop Orforglipron oral GLP-1, HbA1c 1.5%, weight 7.6% IcoSema weekly semaglutide + once-weekly insulin Even more exciting
That depends entirely on reconstitution, since 120 mg is the dry vial content, not a dose
With continued cellular protection over time